Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

Initially, it was only about type 2 diabetes. Semaglutide is the active substance in the Wegovy and Ozempic injections produced by the Danish pharmaceutical company Novo Nordisk. Semaglutide works on ...

L-glutamine, also known as glutamine, is an amino acid. Amino acids are organic compounds often referred to as the building blocks of proteins. They play critical roles in health, such as building ...

People who use semaglutide, the active ingredient in diabetes and weight-loss medications like Ozempic, face twice the risk of developing a serious eye condition that can lead to blindness, according ...

Ferozan has over 20 years of experience writing and editing in the health and wellness sphere. She has worked as a ...

Liraglutide, sold under the brand name Victoza for diabetes, is an earlier iteration in the same class as semaglutide, the active ingredient in Ozempic. Both are sold by Danish drug giant Novo ...

In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

Weight-loss drugs such as semaglutide are increasingly popular among adults, who have flocked to the new medication as an alternative to the traditional – and often ineffective (in implementatio ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Both drugs contain semaglutide, a synthetic version of a hormone known as GLP-1, which the body releases into the intestine when people eat food, reducing feelings of hunger. Ozempic is a Type 2 ...

The experimental drug puts semaglutide, the ingredient in Ozempic and the weight-loss drug Wegovy, together with a medicine called cagrilintide to make the combination Novo Nordisk calls CagriSema.

REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components ...